UBS: BUD APAC (01876) beats expectations in Q1 performance, rated "buy"
Looking ahead to the full year of 2026, management reiterated that increasing sales volume is a top priority. Management also noted that raw material costs for 2026 have been largely offset and plans to improve operational efficiency through cost control measures.
UBS released a research report stating that the first quarter revenue/normalized EBITDA of BUD APAC (01876) was 1.493 billion US dollars/4.63 billion US dollars, a year-on-year decrease of 0.7%/8.1% respectively, better than the bank's and market consensus expectations of 3-6%. The decrease in revenue was mainly due to a slight increase in sales volume year-on-year of 0.1% and a decrease in average selling price year-on-year of 0.8%. The year-on-year decrease in normalized EBITDA profit margin was 2.2 percentage points, mainly attributed to the year-on-year increase of 1.2 percentage points in sales, general, and administrative expenses ratio. UBS set a target price of 8.6 Hong Kong dollars for BUD APAC and maintained a "buy" rating.
UBS mentioned that it participated in the BUD APAC conference call. Looking forward to the full year of 2026, the management reiterated that sales volume growth is a top priority, and also mentioned that raw material costs for 2026 have been largely hedged, and they plan to improve operational efficiency through cost control measures.
Related Articles

New stock news | Weijian Pharmaceutical's Hong Kong IPO prospectus fails to take effect.

New stock news | Haina Pharmaceuticals' Hong Kong stock IPO prospectus invalidated.

CUTIA-B (02487): CU-30101 (local anesthetic lidocaine cream) obtained the drug market approval from the National Medical Products Administration.
New stock news | Weijian Pharmaceutical's Hong Kong IPO prospectus fails to take effect.

New stock news | Haina Pharmaceuticals' Hong Kong stock IPO prospectus invalidated.

CUTIA-B (02487): CU-30101 (local anesthetic lidocaine cream) obtained the drug market approval from the National Medical Products Administration.






